Efficacy News and Research

RSS

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

Babies born to smoking mothers have 47% increase in odds of becoming overweight

Many women are encouraged to quit smoking when they become pregnant using nicotine replacement therapy (NRT) whether as gum, transdermal patches, nasal spray or lozenges.

16 Jan 2014

Research: Some warning labels can make products like cigarettes more appealing

Many products, like cigarettes and medications, are stamped with warning labels alerting consumers to their risks. Common sense suggests these warnings will encourage safer choices.

16 Jan 2014

FTM transgender patients are more likely to have inadequate Pap tests

A new study finds that female-to-male (FTM) transgender patients had over 10 times higher odds of having an inadequate Papanicolaou (Pap) test compared to female patients.

16 Jan 2014

Scientists develop new nasal vaccine that proves effective against whooping cough

Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine.

16 Jan 2014

Researchers develop "smart" hydrogel that can deliver medicine on demand

Researchers at the University of Delaware have developed a "smart" hydrogel that can deliver medicine on demand, in response to mechanical force.

16 Jan 2014

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer.

16 Jan 2014

GLNT study to evaluate abnormal muscle tone caused by neurological disorders

Great Lakes NeuroTechnologies announced today that it is launching a study to determine the feasibility of a clinician-worn glove to objectively evaluate abnormal muscle tone, such as stiff joints or muscle tightness, due to neurological disorders.

16 Jan 2014

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's CE Mark-approved DESolve Novolimus Eluting Coronary Scaffold was performed in Germany by Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany.

15 Jan 2014

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

Biogen Idec today announced that FAMPYRA (prolonged-release fampridine tablets) has been made available in Ireland for the symptomatic treatment of walking impairment in adults with Multiple Sclerosis. FAMPYRA is a prescription drug and is licensed for use in all types of the disease, including the progressive forms. FAMPYRA is available by way of retail pharmacy on a private payment basis.

15 Jan 2014

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

AstraZeneca and Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration approved Farxiga™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

13 Jan 2014

HoLEP effective for overactive bladder symptoms

Research shows that Holmium laser enucleation of the prostate is effective in improving overactive bladder symptoms and urodynamic parameters in men with benign prostatic hyperplasia.

13 Jan 2014

Researchers develop automated venipuncture device that automates phlebotomy procedure

A new medical device has been developed that will provide phlebotomists and clinicians with a technology to enable blood drawing accuracy at first stick. This is particularly important considering the diverse patient demographic each with various levels of difficult venous access.

10 Jan 2014

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient’s own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis.

10 Jan 2014

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.

10 Jan 2014

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.

10 Jan 2014

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance Inc. today announced interim results from its phase 2a pilot study of EB-1020 SR in adult patients with all subtypes of ADHD. With the four week trial fully enrolled and dosing completed in the majority of patients, the results indicate a statistically significant improvement in ADHD symptoms.

10 Jan 2014

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April.

9 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Efficacy News and Research

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Babies born to smoking mothers have 47% increase in odds of becoming overweight

Research: Some warning labels can make products like cigarettes more appealing

FTM transgender patients are more likely to have inadequate Pap tests

Scientists develop new nasal vaccine that proves effective against whooping cough

Researchers develop "smart" hydrogel that can deliver medicine on demand

RTOG phase II clinical trial of Bevacizumab (Avastin) shows positive results for treatment of cervical cancer

GLNT study to evaluate abnormal muscle tone caused by neurological disorders

First commercial implant of Elixir's DESolve Novolimus Eluting Coronary Scaffold performed in Germany

FAMPYRA now available in Ireland for symptomatic treatment of walking impairment in MS patients

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

HoLEP effective for overactive bladder symptoms

Researchers develop automated venipuncture device that automates phlebotomy procedure

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News